CL2013003198A1 - Uso de volasertib, una sal o un hidrato del mismo para preparar un medicamento útil en el tratamiento de malignidades sólidas que incluyen malignidades sólidas avanzadas y metastásicas. - Google Patents

Uso de volasertib, una sal o un hidrato del mismo para preparar un medicamento útil en el tratamiento de malignidades sólidas que incluyen malignidades sólidas avanzadas y metastásicas.

Info

Publication number
CL2013003198A1
CL2013003198A1 CL2013003198A CL2013003198A CL2013003198A1 CL 2013003198 A1 CL2013003198 A1 CL 2013003198A1 CL 2013003198 A CL2013003198 A CL 2013003198A CL 2013003198 A CL2013003198 A CL 2013003198A CL 2013003198 A1 CL2013003198 A1 CL 2013003198A1
Authority
CL
Chile
Prior art keywords
solid malignancies
volasertib
hydrate
prepare
salt
Prior art date
Application number
CL2013003198A
Other languages
English (en)
Inventor
Tillmann Taube
Gerd Michael Munzert
Dorothea Rudolph
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46046245&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2013003198(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of CL2013003198A1 publication Critical patent/CL2013003198A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CL2013003198A 2011-05-13 2013-11-07 Uso de volasertib, una sal o un hidrato del mismo para preparar un medicamento útil en el tratamiento de malignidades sólidas que incluyen malignidades sólidas avanzadas y metastásicas. CL2013003198A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP11165958 2011-05-13

Publications (1)

Publication Number Publication Date
CL2013003198A1 true CL2013003198A1 (es) 2014-06-20

Family

ID=46046245

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2013003198A CL2013003198A1 (es) 2011-05-13 2013-11-07 Uso de volasertib, una sal o un hidrato del mismo para preparar un medicamento útil en el tratamiento de malignidades sólidas que incluyen malignidades sólidas avanzadas y metastásicas.

Country Status (15)

Country Link
US (3) US20130131069A1 (es)
EP (1) EP2707001B1 (es)
JP (1) JP2014513144A (es)
KR (1) KR20140025460A (es)
CN (1) CN103533941A (es)
AR (1) AR086390A1 (es)
AU (1) AU2012257833A1 (es)
BR (1) BR112013029182A2 (es)
CA (1) CA2835717A1 (es)
CL (1) CL2013003198A1 (es)
EA (1) EA201301265A1 (es)
IL (1) IL228882A0 (es)
MX (1) MX2013013059A (es)
UY (1) UY34065A (es)
WO (1) WO2012156283A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060035903A1 (en) 2004-08-14 2006-02-16 Boehringer Ingelheim International Gmbh Storage stable perfusion solution for dihydropteridinones
US20060058311A1 (en) 2004-08-14 2006-03-16 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation
US7439358B2 (en) 2006-02-08 2008-10-21 Boehringer Ingelheim International Gmbh Specific salt, anhydrous and crystalline form of a dihydropteridione derivative
US8546566B2 (en) 2010-10-12 2013-10-01 Boehringer Ingelheim International Gmbh Process for manufacturing dihydropteridinones and intermediates thereof
US9358233B2 (en) 2010-11-29 2016-06-07 Boehringer Ingelheim International Gmbh Method for treating acute myeloid leukemia
US9370535B2 (en) 2011-05-17 2016-06-21 Boehringer Ingelheim International Gmbh Method for treatment of advanced solid tumors
US20150031699A1 (en) 2013-07-26 2015-01-29 Boehringer Ingelheim International Gmbh Treatment of myelodysplastic syndrome
US9867831B2 (en) 2014-10-01 2018-01-16 Boehringer Ingelheim International Gmbh Combination treatment of acute myeloid leukemia and myelodysplastic syndrome

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0797333A (ja) * 1993-08-04 1995-04-11 Takeda Chem Ind Ltd 超分子構造型集合体
NZ542498A (en) 2003-02-26 2009-01-31 Boehringer Ingelheim Pharma Dihydropteridinones, method for the production and use thereof in the form of drugs
US6861422B2 (en) * 2003-02-26 2005-03-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions
US20060074088A1 (en) * 2004-08-14 2006-04-06 Boehringer Ingelheim International Gmbh Dihydropteridinones for the treatment of cancer diseases
US20060035903A1 (en) 2004-08-14 2006-02-16 Boehringer Ingelheim International Gmbh Storage stable perfusion solution for dihydropteridinones
US20060058311A1 (en) * 2004-08-14 2006-03-16 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation
US7439358B2 (en) 2006-02-08 2008-10-21 Boehringer Ingelheim International Gmbh Specific salt, anhydrous and crystalline form of a dihydropteridione derivative

Also Published As

Publication number Publication date
WO2012156283A1 (en) 2012-11-22
EA201301265A1 (ru) 2014-05-30
UY34065A (es) 2012-11-30
AR086390A1 (es) 2013-12-11
JP2014513144A (ja) 2014-05-29
CA2835717A1 (en) 2012-11-22
IL228882A0 (en) 2013-12-31
AU2012257833A1 (en) 2013-10-31
MX2013013059A (es) 2014-02-20
EP2707001B1 (en) 2016-12-21
BR112013029182A2 (pt) 2017-01-31
US20190290652A1 (en) 2019-09-26
KR20140025460A (ko) 2014-03-04
EP2707001A1 (en) 2014-03-19
US20160303131A1 (en) 2016-10-20
CN103533941A (zh) 2014-01-22
US20130131069A1 (en) 2013-05-23

Similar Documents

Publication Publication Date Title
CL2013003198A1 (es) Uso de volasertib, una sal o un hidrato del mismo para preparar un medicamento útil en el tratamiento de malignidades sólidas que incluyen malignidades sólidas avanzadas y metastásicas.
IL304851A (en) Tazematostat in combination with an acceptable treatment factor for use in the treatment of cancer
CL2013003230A1 (es) Uso de volasertib, una sal o un hidrato del mismo para preparar un medicamento útil en el tratamiento de tumores sólidos avanzados y/o metastásicos.
HK1216251A1 (zh) 吡唑並吡咯烷衍生物及其治病作用
CO6801769A2 (es) Cmbinaciones que comprenden brexpiprazol o una sal del mismo y un segundo fármaco para uso en el tratamiento de un trastorno del snc
CL2013003306A1 (es) Uso de 4-amino-5-fluoro-3-[6-(4-metil-piperazin-1-il)-1h-bencimidazol-2-il]-1h-quinolin-2-ona, un tautómero o sal de la misma para preparar un medicamento útil para el tratamiento de carcinoma adenoide quístico.
HK1212248A1 (en) Inhibitors of met, vegfr and ret for use in the treatment of lung adenocarcinoma metvegfr ret
HK1221178A1 (zh) 卡博替尼劑型及其在癌症治療中的使用
GB2513167B (en) Tetrahydrocannabivarin for use in the treatment of nausea and vomiting
CL2013001602A1 (es) Metodo para reducir o inhibir la progresion del nivel de fatiga en pacientes con esclerosis multiple y para proporcionarles neuroproteccion que comprende administrar oralmente laquinimod o una sal del mismo; laquinimod para reducir el nivel de fatiga, mejorar el estado funcional y entregar neuroproteccion en esclerosis multiple.
BR112015003397A2 (pt) composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente.
CL2015003223A1 (es) Procedimiento para proporcionar una caracteristica de seguridad a un documento de seguridad, y el documento de seguridad
CL2013003082A1 (es) Uso de una combinación que comprende aflibercept, ácido folínico, 5-fluorouracilo (5-fu) e irinotecan para preparar un medicamento útil para tratar el cáncer colorrectal (ccr) o un síntoma del mismo en un paciente que lo necesite.
CL2015000294A1 (es) Combinaciones farmaceuticas que comprenden un inhibidor de b-raf, un inhibidor del receptor del factor de crecimiento epidermico y opcionalmente un inhibidor pi3halpha y uso en el tratamiento de una enfermedad proliferativa.
PL3004108T3 (pl) Pochodne pirazolo-pirolidyn-4-onu jako inhibitory BET oraz ich zastosowanie w leczeniu chorób
PL3004112T3 (pl) Pochodne pirazolo-pirolidyn-4-onu oraz ich zastosowanie w leczeniu choroby
HRP20181490T1 (hr) Spojevi 1, 3, 4-tiadiazola i njihova upotreba u liječenju raka
CL2015001202A1 (es) Compuestos derivados de oxazolidin-2-ona-pirimidina; composicion y combinacion farmaceutica y uso en el tratamiento del cancer.
CL2013002193A1 (es) Uso de un producto que comprende macitentano o una sal del mismo en combinacion con un agente alquilante o un inhibidor mitotico para preparar un medicamento util en el tratamiento de glioma maligno.
CL2014003525A1 (es) Composicion farmaceutica que comprende fimasartan, hidroclorotiazida y un aglutinante; procedimiento de preparacion; su uso en el tratamiento de hipertension.
GB2510477B (en) Formulations for use in the treatment of chronic fatigue and associated conditions, etc
CL2016002083A1 (es) Composición antifúngica tópica para el tratamiento de onicomicosis
BR112015003192A2 (pt) arry-520 para uso no tratamento de câncer em um paciente com baixa aag
ZA201600894B (en) Use of 3-carboxy-n-ethyl-n,n-dimethylpropan-1-aminium or a pharmaceutically acceptable salt thereof in the prevention and treatment of diabetes
AP2015008849A0 (en) Pyrazolopyrrolidine derivatives and their use in the treatment of disease